Rapid and Inexpensive Paper-Based Test Simultaneously Quantifies Multiple Cardiac Biomarkers
By LabMedica International staff writers Posted on 02 May 2023 |

Centralized lab testing has long been the go-to method for diagnosing common illnesses. However, this approach often necessitates costly medical equipment and complex procedures that can only be carried out by highly trained professionals within a medical facility. These factors prolong testing time and hinder the widespread application of diagnostics in remote and resource-poor areas due to limited access to central labs. In response to these challenges, point-of-care (POC) sensors were developed as alternative diagnostic tools, characterized by their simplicity, rapid operation, compact size, and affordability. The most prevalent type of POC tests are paper-based sensors, also known as lateral flow assays (LFAs), where the injected sample fluid flows horizontally and reacts with specific test regions (test lines) to generate, for instance, a color change. Despite their ease of use and cost-effectiveness, existing LFAs have certain drawbacks, such as lower sensitivity and challenges with multiplexed testing for disease biomarkers.
To address these shortcomings, researchers at University of California (UCLA, Los Angeles, CA, USA) have devised a novel paper-based biosensor that utilizes a fluorescent multiplexed vertical flow assay to rapidly and simultaneously measure three cardiac biomarkers from human serum samples. This new paper-based POC sensor's vertical flow design allows for multiple test regions with up to 100 individual test spots on a single disposable cartridge. The powerful sensor operates with just a small serum droplet and can be easily used by a minimally trained individual in under 15 minutes per patient. Along with its multiplexing capabilities, the paper-based sensor also boasts high sensitivity, achieving a detection limit better than ~0.5 ng/mL for each biomarker — less than one billionth of half a gram per milliliter of serum.
Additionally, the UCLA researchers have created a mobile phone-based, low-cost handheld fluorescence reader and a deep learning-assisted signal analysis pipeline to automatically and accurately quantify the three target biomarkers in a user-friendly manner. The team tested their paper-based multiplexed sensor for the quantification of three biomarkers of acute coronary syndrome (ACS), including myoglobin, creatine kinase-MB (CK-MB), and heart-type fatty acid binding protein (FABP). ACS is a cardiovascular condition that demands prompt diagnosis in emergency situations, and these target markers are released into the bloodstream shortly after symptom onset. The newly-developed paper-based sensor was evaluated on human serum samples, and the measured concentrations for all three cardiac biomarkers aligned well with the benchmark measurements obtained by a standard laboratory test. Given its accuracy, speed, user-friendliness, and affordability, this deep learning-enabled paper-based multiplexed sensor offers an attractive POC testing option for various applications in remote and resource-limited settings.
“Compared to a commonly used linear calibration method, our deep learning-based analysis benefits from the function approximation power of neural networks to learn non-trivial relationships between the multiplexed fluorescence signals from the paper-based sensor and the underlying analyte concentrations in serum,” said Artem Goncharov, a graduate student at UCLA Electrical & Computer Engineering Department. “As a result, we have accurate quantitative measurements for all three biomarkers of interest despite the background noise present in clinical serum samples.”
Related Links:
UCLA
Latest Molecular Diagnostics News
- Simple Blood Test Improves Heart Attack and Stroke Risk Prediction
- Blood Biomarker Test Could Detect Genetic Predisposition to Alzheimer’s
- Novel Autoantibody Against DAGLA Discovered in Cerebellitis
- Blood Test Could Identify Patients at Risk for Severe Scleroderma
- Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
- Rapid Blood Test Identifies Pre-Symptomatic Patients with Parkinson’s Disease
- Blood Test for Early Alzheimer's Detection Achieves Over 90% Accuracy
- RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
- First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
- Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
- Novel Point-of-Care Technology Delivers Accurate HIV Results in Minutes
- Blood Test Rules Out Future Dementia Risk
- D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism
- New Biomarkers to Improve Early Detection and Monitoring of Kidney Injury
- Chemiluminescence Immunoassays Support Diagnosis of Alzheimer’s Disease
- Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Spit Test More Accurate at Identifying Future Prostate Cancer Risk
Currently, blood tests that measure the level of a protein called prostate-specific antigen (PSA) are commonly used to identify men at higher risk for prostate cancer. This test is typically used based... Read more
DNA Nanotechnology Boosts Sensitivity of Test Strips
Since the Covid-19 pandemic, most people have become familiar with paper-based rapid test strips, also known as lateral flow immunoassays (LFIAs). These tests are used to quickly detect biomarkers that... Read more
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more